## Ahmet Emre EÅ<mark></mark>Kazan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2187799/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dasatinibâ€induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology, 2018, 84, 835-845.	2.4	48
2	Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. Annals of Hematology, 2016, 95, 1751-1756.	1.8	44
3	COVIDâ€19 presenting with immune thrombocytopenia: A case report and review of the literature. Journal of Medical Virology, 2021, 93, 43-45.	5.0	41
4	New drugs approved for acute myeloid leukaemia in 2018. British Journal of Clinical Pharmacology, 2019, 85, 2689-2693.	2.4	39
5	<p>Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura</p> . Drug Design, Development and Therapy, 2019, Volume 13, 1251-1258.	4.3	38
6	Bone marrow transplantation for Behcet's disease: a case report and systematic review of the literature. Rheumatology, 2014, 53, 1136-1141.	1.9	37
7	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. Leukemia Research, 2014, 38, 781-787.	0.8	33
8	Novel therapeutic approaches in chronic myeloid leukemia. Leukemia Research, 2020, 91, 106337.	0.8	33
9	Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Design, Development and Therapy, 2016, Volume 10, 3355-3361.	4.3	32
10	Midostaurin in <i>FLT3</i> -Mutated Acute Myeloid Leukemia. New England Journal of Medicine, 2017, 377, 1901-1903.	27.0	32
11	The Role of Nitric Oxide in Doxorubicin-Induced Cardiotoxicity: Experimental Study. Turkish Journal of Haematology, 2014, 31, 68-74.	0.5	27
12	Spondylodiscitis: evaluation of patients in a tertiary hospital. Journal of Infection in Developing Countries, 2014, 8, 1272-1276.	1.2	26
13	Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Therapeutic Advances in Hematology, 2017, 8, 237-243.	2.5	26
14	Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica, 2011, 96, e15-e15.	3.5	25
15	The impact of <i>BCRâ€ABL1</i> transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. Cancer, 2018, 124, 3806-3818.	4.1	23
16	Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature. Transfusion, 2012, 52, 1715-1720.	1.6	20
17	Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 804-811.	0.4	20
18	Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology, 2018, 23, 212-220.	1.5	20

#	Article	IF	CITATIONS
19	Generics in chronic myeloid leukemia: current arguments for and against and the established evidence. Expert Review of Hematology, 2014, 7, 697-699.	2.2	18
20	Acute Acalculous Cholecystitis due to Viral Hepatitis A. Case Reports in Infectious Diseases, 2013, 2013, 1-4.	0.5	17
21	First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. British Journal of Haematology, 2014, 167, 139-141.	2.5	17
22	Brucellar pericarditis: a report of four cases and review of the literature. International Journal of Infectious Diseases, 2013, 17, e428-e432.	3.3	16
23	Two Cases of Autoimmune Hemolytic Anemia Secondary to Brucellosis: A Review of Hemolytic Disorders in Patients with Brucellosis. Internal Medicine, 2014, 53, 1153-1158.	0.7	16
24	Tyrosine kinase inhibitor (TKI) therapy for newly-diagnosed patients with chronic myeloid leukemia: focusing on TKI discontinuation due to adverse events – is better always good?. Expert Review of Hematology, 2017, 10, 583-586.	2.2	16
25	Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. Blood Advances, 2021, 5, 3344-3353.	5.2	16
26	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. Turkish Journal of Haematology, 2013, 30, 351-358.	0.5	14
27	Cyclosporin <scp>A</scp> therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. Transfusion, 2013, 53, 1586-1593.	1.6	14
28	The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leukemia and Lymphoma, 2014, 55, 2935-2937.	1.3	14
29	Postoperative thrombotic thrombocytopenic purpura. Surgery Today, 2015, 45, 8-16.	1.5	14
30	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. Turkish Journal of Haematology, 2016, 33, 216-222.	0.5	14
31	Novel <i>BCR-ABL1</i> tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Expert Review of Hematology, 2021, 14, 975-978.	2.2	14
32	Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. Expert Review of Quality of Life in Cancer Care, 2016, 1, 353-359.	0.6	13
33	Essential Thrombocythemia and Multiple Myeloma: Two Rare Diseases in One Patient. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 442-445.	0.4	12
34	Cytopenia in adult brucellosis patients. Indian Journal of Medical Research, 2018, 147, 73.	1.0	12
35	Deep sequencing of <i>BCR-ABL1</i> kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. Leukemia and Lymphoma, 2019, 60, 200-207.	1.3	11
36	Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?. Expert Review of Hematology, 2020, 13, 1035-1038.	2.2	11

#	Article	IF	CITATIONS
37	COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey. Turkish Journal of Haematology, 2021, 38, 79-81.	0.5	11
38	Evolving treatment strategies in CML – moving from early and deep molecular responses to TKI discontinuation and treatmentâ€free remission: is there a need for longerâ€term trial outcomes?. British Journal of Clinical Pharmacology, 2018, 84, 1635-1638.	2.4	10
39	Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities—Which TKI is the safest?. British Journal of Clinical Pharmacology, 2019, 85, 2241-2243.	2.4	10
40	<p>Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes</p> . Journal of Blood Medicine, 2020, Volume 11, 319-326.	1.7	10
41	Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions. Leukemia Research, 2022, 114, 106808.	0.8	10
42	Primary Cutaneous Immunocytoma/Marginal Zone B-Cell Lymphoma: A Case with Unusual Course. American Journal of Dermatopathology, 2004, 26, 119-122.	0.6	9
43	Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease. Case Reports in Gastroenterology, 2011, 5, 262-266.	0.6	9
44	Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. Turkish Journal of Haematology, 2015, 32, 243-250.	0.5	9
45	Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?. Expert Review of Clinical Pharmacology, 2021, 14, 1183-1188.	3.1	9
46	Tocilizumab in COVID-19: The CerrahpaÅŸa-PREDICT score. Journal of Infection and Chemotherapy, 2021, 27, 1329-1335.	1.7	9
47	Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. Journal of Medical Case Reports, 2009, 3, 7306.	0.8	8
48	Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study. ISRN Hematology, 2013, 2013, 1-9.	1.6	8
49	Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?. Expert Review of Hematology, 2016, 9, 919-921.	2.2	8
50	Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. Oncology and Therapy, 2019, 7, 95-100.	2.6	8
51	Hypereosinophilic Syndrome Associated with Simultaneous Intracardiac Thrombi, Cerebral Thromboembolism and Pulmonary Embolism. Internal Medicine, 2012, 51, 309-313.	0.7	7
52	Thrombotic Thrombocytopenic Purpura After Prophylactic Cefuroxime Axetil Administered in Relation to a Liposuction Procedure. Aesthetic Plastic Surgery, 2012, 36, 464-467.	0.9	7
53	Radotinib in the treatment of chronic phase chronic myeloid leukemia patients. Haematologica, 2015, 100, e39-e39.	3.5	7
54	Treatment of patients with immune thrombocytopenia admitted to the emergency room. International Journal of Hematology, 2016, 104, 216-222.	1.6	7

#	Article	IF	CITATIONS
55	Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. Turkish Journal of Haematology, 2017, 34, 291-299.	0.5	7
56	Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. Turkish Journal of Gastroenterology, 2015, 25, 233-233.	1.1	7
57	Comparison of International Prognostic Index and NCCN-IPI in 324 patients with <i>de novo</i> diffuse large B-cell lymphoma: a multi-center retrospective analysis. Leukemia and Lymphoma, 2016, 57, 1211-1214.	1.3	6
58	Tyrosine Kinase Inhibitor–Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961986692.	1.7	6
59	Asciminib as a new option in the treatment of chronic myeloid leukemia. Future Oncology, 2021, 17, 5003-5005.	2.4	6
60	Treatment and Outcome of Primary and Secondary Thrombotic Microangiopathies. American Journal of Nephrology, 2015, 41, 427-428.	3.1	5
61	Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. Journal of Clinical Pathology, 2016, 69, 810-816.	2.0	5
62	An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission. Expert Review of Hematology, 2019, 12, 477-480.	2.2	5
63	Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology, 2020, 99, 2671-2677.	1.8	5
64	Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVIDâ€19 pandemic. British Journal of Clinical Pharmacology, 2020, 86, 1790-1792.	2.4	5
65	Bosutinib – related pleural effusion in patients with chronic myeloid leukemia. Expert Opinion on Drug Safety, 2021, 20, 379-381.	2.4	5
66	Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. Turkish Journal of Haematology, 2011, 28, 186-192.	0.5	4
67	ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. Turkish Journal of Haematology, 2011, 28, 97-102.	0.5	4
68	Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. Annals of Hematology, 2012, 91, 305-306.	1.8	4
69	Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?. Leukemia and Lymphoma, 2015, 56, 2995-2996.	1.3	4
70	Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single Institution Experience. Balkan Medical Journal, 2018, 35, 417-421.	0.8	4
71	Asciminib in chronic myeloid leukemia: many questions still remain to be answered. Blood Cancer Journal, 2021, 11, 81.	6.2	4
72	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience, Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 549-557	0.4	4

#	Article	IF	CITATIONS
73	Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting. Expert Review of Hematology, 2022, 15, 97-106.	2.2	4
74	Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia. Biotechnology and Biotechnological Equipment, 2009, 23, 1515-1520.	1.3	3
75	Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?. Leukemia Research, 2011, 35, e145-e146.	0.8	3
76	Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. Case Reports in Oncology, 2011, 4, 439-444.	0.7	3
77	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turkish Journal of Haematology, 2014, 31, 374-380.	0.5	3
78	The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. Leukemia and Lymphoma, 2015, 56, 1182-1183.	1.3	3
79	Pleural tuberculosis in a patient with untreated type 1 Gaucher disease. Journal of Infection and Chemotherapy, 2016, 22, 53-57.	1.7	3
80	Generic imatinib in the treatment of chronic myeloid leukemia: CerrahpaÅŸa experience. Journal of Oncology Pharmacy Practice, 2016, 22, 382-384.	0.9	3
81	Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed-Refractory to IMiDs and Proteasome Inhibitors. Turkish Journal of Haematology, 2017, 34, 233-238.	0.5	3
82	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e241.	0.4	3
83	The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e377-e384.	0.4	3
84	Copy-number variations in adult patients with chronic immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1277-1287.	2.2	3
85	Therapyâ€related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. Cancer Reports, 2020, 3, e1282.	1.4	3
86	Bosutinib – an effective and safe treatment option in the management of chronic myeloid leukemia. Future Oncology, 2020, 16, 4425-4428.	2.4	3
87	Candida esophagitis incidentally detected by 18Fâ€FDG PET/CT in a patient with CNS lymphoma. Clinical Case Reports (discontinued), 2021, 9, e04322.	0.5	3
88	Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. Blood, 2011, 118, 1692-1692.	1.4	3
89	Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias. Blood, 2015, 126, 4037-4037.	1.4	3
90	Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?. Turkish Journal of Haematology, 2015, 32, 213-9.	0.5	3

#	Article	IF	CITATIONS
91	Management of chronic myeloid leukemia in myeloid blastic phase with novel therapies: a systematic literature review. Expert Review of Hematology, 2022, 15, 423-429.	2.2	3
92	Intracranial mass in a patient with thalassaemia major. British Journal of Haematology, 2011, 152, 126-126.	2.5	2
93	Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report. Journal of Medical Case Reports, 2012, 6, 423.	0.8	2
94	Successful Management of Chronic Refractory Immune Thrombocytopenia with Laparoscopic Splenectomy in a Patient with Acute Promyelocytic Leukemia. Indian Journal of Hematology and Blood Transfusion, 2013, 29, 173-177.	0.6	2
95	The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment. Leukemia and Lymphoma, 2015, 56, 1554-1555.	1.3	2
96	Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha. Indian Journal of Hematology and Blood Transfusion, 2016, 32, 272-277.	0.6	2
97	The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. Journal of Medical Economics, 2018, 21, 709-711.	2.1	2
98	Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?. Leukemia Research, 2018, 74, 55-56.	0.8	2
99	The tolerability issue of generic imatinib in patients with chronic myeloid leukemia (Comment on Adi J.) Tj ETQq1	1	.4 <sub>2</sub> gBT /Ove
100	Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. Leukemia, 2020, 34, 3426-3427.	7.2	2
101	Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. Journal of Oncology Pharmacy Practice, 2020, 26, 2042-2046.	0.9	2
102	What is the best treatment approach for sporadic lateâ€onset nemaline myopathy associated with "monoclonal gammopathy of neurological significance�. International Journal of Cancer, 2021, 148, 2638-2639.	5.1	2
103	The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors – What is New in the Battle of CML?. European Oncology and Haematology, 2015, 11, 30.	0.0	2
104	Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia. Turkish Journal of Haematology, 2013, 30, 435-436.	0.5	2
105	Interstitial pneumonitis in a patient with chronic myeloid leukemia. Turkish Journal of Haematology, 2013, 30, 435-6.	0.5	2
106	Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia. Turkish Journal of Haematology, 2013, 30, 435-436.	0.5	2
107	B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node. Turkish Journal of Haematology, 2013, 30, 98-99.	0.5	1
108	IgD Multiple Myeloma, Descriptive Report of Eight Cases, Single Centre Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e313.	0.4	1

#	Article	IF	CITATIONS
109	Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?. Leukemia and Lymphoma, 2017, 58, 2019-2020.	1.3	1
110	Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. Cancer, 2018, 124, 4260-4261.	4.1	1
111	ls measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?. Leukemia and Lymphoma, 2019, 60, 2094-2095.	1.3	1
112	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. Laboratory Medicine, 2020, 51, 259-264.	1.2	1
113	Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it costâ€effective?. Cancer, 2020, 126, 256-259.	4.1	1
114	A clinical appraisal of chronic myeloid leukaemia (CML)â€related death and CMLâ€specific death—Are they synonymous?. International Journal of Clinical Practice, 2021, 75, e14217.	1.7	1
115	New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 casesâ€, Translational Oncology, 2021, 14, 101098.	3.7	1
116	Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from EÅŸkazan et al. Journal of Thrombosis and Haemostasis, 2021, 19, 2644-2646.	3.8	1
117	Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance. Blood, 2013, 122, 384-384.	1.4	1
118	Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia. Blood, 2015, 126, 2783-2783.	1.4	1
119	PB1929 POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TYROSINE KINASE INHIBITOR THERAPY WITH IMATINIB. HemaSphere, 2019, 3, 877.	2.7	1
120	The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib. Blood, 2019, 134, 4316-4316.	1.4	1
121	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behcet's Disease. Molecular Imaging and Radionuclide Therapy, 2022, 31, 57-59.	0.7	1
122	Spotlight Commentary – Voxelotor: A new kid on the block in the treatment of sickle cell disease. British Journal of Clinical Pharmacology, 2022, 88, 2564-2565.	2.4	1
123	The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Turkish Journal of Haematology, 2012, 29, 242-247.	0.5	Ο
124	Carfilzomib in Relapsed/Refractory Multiple Myeloma, Single Center Experience. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e306-e307.	0.4	0
125	Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country. Clinical Therapeutics, 2016, 38, 680-681.	2.5	0
126	Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. European Journal of Clinical Pharmacology, 2016, 72, 1537-1538.	1.9	0

#	Article	IF	CITATIONS
127	Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. Expert Opinion on Pharmacotherapy, 2017, 18, 325-326.	1.8	0
128	Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Leukemia and Lymphoma, 2017, 58, 2516-2517.	1.3	0
129	Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e63-e64.	0.4	0
130	Comment and response to: the significance of early warning in chronic myeloid leukemia. Expert Review of Hematology, 2018, 11, 267-268.	2.2	0
131	Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib. International Journal of Clinical Oncology, 2018, 23, 400-401.	2.2	0
132	Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword. Acta Oncológica, 2019, 58, 123-124.	1.8	0
133	Coexistence of Hermansky-Pudlak syndrome andJAK2V617F-positive essential thrombocythemia. Ultrastructural Pathology, 2019, 43, 94-98.	0.9	0
134	Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?. Biology of Blood and Marrow Transplantation, 2020, 26, e237-e238.	2.0	0
135	Platelet count threshold for lumbar puncture: Does one size really fit all?. Transfusion, 2021, 61, 329-329.	1.6	0
136	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naÃ <sup>-</sup> ve patients with chronic lymphocytic leukemia. Turkish Journal of Medical Sciences, 2021, 51, 348-354.	0.9	0
137	KRONİK LENFOSİTİK LÖSEMİ TANILI HASTALARDA KİLLER İMMÜNOGLOBULİN LİKE RESEPTÖR OTOİMMÜN OLAYLAR İLE İLİŞKİSİ. İstanbul Tıp Fakültesi Dergisi, 2021, 84, .	GEN DÜ	ZEYLERİ VE
138	Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis. Hematology, Transfusion and Cell Therapy, 2021, , .	0.2	0
139	Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience. Blood, 2011, 118, 5223-5223.	1.4	0
140	CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia. Blood, 2011, 118, 4603-4603.	1.4	0
141	Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience. Blood, 2011, 118, 4429-4429.	1.4	0
142	The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia. Blood, 2014, 124, 5648-5648.	1.4	0
143	Second primary malignancies in chronic myeloid leukemia patients. Journal of Cancer Research and Therapeutics, 2015, 11, 1042.	0.9	0
144	Posttransplant Secondary Neoplasms: A Single Center Experience. Blood, 2015, 126, 5485-5485.	1.4	0

#	Article	IF	CITATIONS
145	Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency. Blood, 2015, 126, 4685-4685.	1.4	0
146	New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition. Blood, 2015, 126, 77-77.	1.4	0
147	Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia. Blood, 2016, 128, 1905-1905.	1.4	Ο
148	The Management of Chronic Myeloid Leukaemia (CML) Patients with Refractory Disease – Focusing on the Opinions of CML-treating Physicians. European Oncology and Haematology, 2017, 13, 15.	0.0	0
149	Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience. Turkish Journal of Haematology, 0, , .	0.5	Ο
150	Management of Major Surgical Procedures in Patients with Hemophilia: A Single-Center Experience of 49 Procedures. Blood, 2019, 134, 4933-4933.	1.4	0
151	Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML. Future Oncology, 2020, 16, 887-889.	2.4	0
152	Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia. Turkish Journal of Haematology, 2021, 38, 226-227.	0.5	0
153	The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience. Blood, 2021, 138, 1394-1394.	1.4	0
154	Treatment Responses, Toxicity and Survival in Patients with Classical Hodgkin Lymphoma Aged 50 Years and Older: A Single-Center Experience over 2 Decades. Blood, 2021, 138, 4541-4541.	1.4	0
155	The Impact of EUTOS Long-Term Survival (ELTS) Score on Predicting Progression and Survival Among Turkish Patients with Chronic Myeloid Leukemia. Blood, 2021, 138, 4600-4600.	1.4	Ο
156	Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML.―by Yamatani etÂal Translational Oncology, 2022, 19, 101394.	3.7	0
157	Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer―by Meng etÂal Translational Oncology, 2022, 20, 101403	3.7	0
158	Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades. Cancer Management and Research, 0, Volume 14, 1911-1921.	1.9	0
159	A new dawn for upfront autologous <scp>SCT</scp> in <scp>NK</scp> /T ell lymphomas: One more step forward in reasoning. International Journal of Cancer, 2022, 151, 661-664.	5.1	0